Results 141 to 150 of about 102,880 (256)

Endoscopic small bowel therapies for type 2 diabetes

open access: yesNutrition in Clinical Practice, Volume 41, Issue 5, Page 1296-1306, October 2026.
Abstract Type 2 diabetes is a global epidemic despite current medical treatments. Many patients are not responsive to medications, and patients with obesity are hesitant about bariatric surgery. Studies investigating the metabolic effects of Roux‐en‐Y gastric bypass have increasingly demonstrated that the duodenum plays a key role in the ...
Roma Patel   +4 more
wiley   +1 more source

An Expert Consensus Framework for a Database on Ileal Amino Acid Digestibility and Protein Quality Scoring From Foods Consumed by Humans

open access: yes
International audienceObjectives: Food Protein Quality is best measured by the amino acid scoring that relates their indispensable amino acid content to a reference profile after correction for digestibility.
Han, Fei   +16 more
core  

Gastrointestinal adverse effects of GLP‐1 receptor agonists and dual GIP/GLP‐1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents

open access: yesNutrition in Clinical Practice, Volume 41, Issue 5, Page 1318-1333, October 2026.
Abstract Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 receptor agonists have transformed the management of type 2 diabetes and obesity. Gastrointestinal (GI) adverse events are the most common limitation of these therapies and a leading cause of discontinuation ...
Vikash Singhani   +6 more
wiley   +1 more source

Clinical and Sociodemographic Factors Associated With Peristomal Skin Complications in Patients With Ostomies: A Cross‐Sectional Study

open access: yesNursing Open, Volume 13, Issue 10, October 2026.
ABSTRACT Aim To analyse the prevalence of peristomal skin complications and identify clinical and sociodemographic factors associated with their occurrence in patients with ostomies. Design Descriptive cross‐sectional study conducted in 17 Spanish hospitals.
Claudia Cuevas‐Sánchez   +11 more
wiley   +1 more source

Digestibilidade ileal verdadeira da proteína em frangos de corte sob dietas com diferentes níveis de proteína bruta = True ileal protein digestibility in broilers fed diets with different crude protein levels

open access: yesActa Scientiarum: Animal Sciences, 2006
A digestibilidade ileal aparente (DIA-PB) e verdadeira (DIV-PB) da proteína bruta (PB) foram determinadas em frangos de 39 dias de idade sob 4 dietas à base de milho e farelo de soja com níveis de PB variando entre 19,8 e 23,5% (4 repetições de 8 frangos/
Marson Bruck Warpechowski   +4 more
doaj  

The Bile Acid Signaling Axis: Deciphering the Roles of FXR and TGR5 in Hepatic Steatosis, Fibrosis, and Cancer

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT Bile acids (BAs) serve not only as emulsifiers for lipid digestion but also as essential signaling molecules, governing various physiological and pathological processes through their interaction with the farnesoid X receptor (FXR) and the takeda G protein‐coupled receptor 5 (TGR5).
Jie Liu   +6 more
wiley   +1 more source

Transplantation of Elderly Human Gut Microbiota Into Pigs Reprograms Intestinal Barrier Function, Plasma Metabolome, and Gut Mucosal Transcriptomic Landscape

open access: yesAging Cell, Volume 25, Issue 10, October 2026.
Elderly human donor microbiota disrupts intestinal barrier integrity and reshapes host metabolic and mucosal transcriptional profiles in human microbiota‐associated pigs. Integrated multi‐omics analyses identify coordinated microbial, metabolic, and host alterations associated with age‐related intestinal decline.
Jiaxin Wang   +19 more
wiley   +1 more source

Review Article: Immune Effector Cell‐Mediated Enterocolitis Following CAR‐T Cell Therapy—Clinical Features, Pathophysiology and Management

open access: yesAlimentary Pharmacology &Therapeutics, Volume 64, Issue 8, Page 1046-1057, October 2026.
Immune effector cell‐mediated enterocolitis is an emerging complication of CAR‐T therapy. This review summarizes its epidemiology, pathophysiology, diagnosis, endoscopic and histopathologic features, and evidence‐based management, emphasizing early recognition, multidisciplinary intervention, and step‐up therapy.
John A. Damianos   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy